Table 1 Demographic and clinical characteristics at inclusion in the study
Characteristics | AD-AD 26 | MCI-AD 25 | MCI-MCI 23 | CTR 25 | p-value |
|---|---|---|---|---|---|
Gender, n (%) | |||||
Female | 13 (50.0) | 14 (56.0) | 10 (43.5) | 15 (60.0) | |
Male | 13 (50.0) | 11 (44.0) | 13 (56.5) | 10 (40.0) | 0.68 |
Age at inclusion | |||||
(mean ± SD) | 64.2 ± 6.2 | 63.7 ± 4.4 | 65.4 ± 6.1 | 67.3 ± 5.0 | 0.10 |
Age at onset | |||||
(mean ± SD) | 61.3 ± 6.3 | 61.0 ± 4.5 | 62. 9 ± 6.7 | na | 0.50 |
Duration of symptoms | |||||
(mean ± SD) | 3.0 ± 1.8 | 2.8 ± 1.0 | 2.9 ± 2.3 | na | 0.94 |
Ten Word Test (delayed recall) | |||||
(mean ± SD) | 1.6 ± 1.6 | 2.1 ± 1.8 | 3.8 ± 1.8 | 7.0 ± 1.7 | <0.0005 |
MMSE, n (%) | |||||
< 27 | 24 (92.7) | 12 (48.0) | 4 (17.4) | 0 (0) | |
≥ 27 | 2 (7.7) | 13 (52.0 ) | 19 (82.6) | 25 (100.0) | <0.0005 |
APOE ɛ4 carrier | |||||
n (%) | 21 (80.8) | 19 (76.0) | 12 (54.5) | 7 (28.0) | <0.0005 |
Aβ42 (pg/mL) | 498.7 ± 208.5 | 535.0 ± 176.3 | 647.7 ± 344.5 | 1080.5 ± 266.1 | <0.0005 |
Aβ40 (pg/mL) | 15265 ± 5386 | 15003 ± 4453 | 14216 ± 8073 | 18207 ± 6595 | 0.24 |
T-tau (pg/mL) | 769.0 ± 405.4 | 733.7 ± 515.5 | 369.0 ± 345.6 | 297.9 ± 129.9 | <0.0005 |
P-tau (pg/mL) | 96.6 ± 35.6 | 90.6 ± 33.8 | 60.1 ± 27.8 | 57.0 ± 16.8 | <0.0005 |